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Background: The smoking-thrombolysis paradox refers to a better outcome in smokers
who suffer from acute ischemic stroke (AIS) following treatment with thrombolysis.
However, studies on this subject have yielded contradictory results and an interaction
analysis of exposure to smoking and thrombolysis in a large, multicenter database
is lacking.
Methods: Consecutive AIS patients admitted within 12 h of symptom onset between
2009 and 2014 from the prospective, multicenter stroke registry (Dutch String-of-Pearls
Stroke Study) were included for this analysis. We performed a generalized linear model for
functional outcome 3 months post-stroke depending on risk of the exposure variables
(smoking yes/no, thrombolysis yes/no). The following confounders were adjusted for:
age, smoking, hypertension, atrial fibrillation, diabetes mellitus, stroke severity, and
stroke etiology.
Results: Out of 468 patients, 30.6% (N = 143) were smokers and median baseline
NIHSS was 3 (interquartile range 1–6). Smoking alone had a crude and adjusted relative
risk (RR) of 0.99 (95% CI 0.89–1.10) and 0.96 (95% CI 0.86–1.01) for good outcome
(modified Rankin Score ≤2), respectively. A combination of exposure variables (smoking
and thrombolysis) did not change the results significantly [crude RR 0.87 (95% CI
0.74–1.03], adjusted RR 1.1 (95%CI 0.90–1.30)]. Smoking alone had an adjusted RR
of 1.2 (95% CI 0.6–2.7) for recanalization following thrombolysis (N = 88).
Conclusions: In patients with mild to moderate AIS admitted within 12 h of symptom
onset, smoking did not modify treatment effect of thrombolysis.
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INTRODUCTION
The so-called smoking-paradox of an improved outcome
following thrombolysis was first described in smokers with
myocardial infarction (1, 2). This phenomenon has resurfaced
as a topic of interest in the scientific community as a
handful of recent studies have reported similar observations
in acute ischemic stroke patients treated with recombinant
tissue plasminogen activator (r-tPA) as well as endovascular
therapies (3–6).
The mechanism underlying the pathophysiology of the
smoking-thrombolysis paradox remains unclear. Some attribute
the observed phenomenon to a systematic lack of adjustment of
confounding factors i.e., lower clinical risk profiles of smokers
due to younger age and fewer comorbidities (7, 8). Others argue
that there is substantial evidence supporting an alteration of clot
dynamics (9, 10) caused by smoke exposure leading to enhanced
tPA efficacy in patients with this risk factor.
As of yet, the studies on this subject have yielded contradictory
results (3–8, 11, 12). Most likely, there is a cumulative effect
of younger age, lower clinical risk profiles, and more aggressive
treatment effect that account for the smoking-thrombolysis
paradox. However, a large comprehensive interaction analysis of
exposure to smoking and treatment with thrombolysis is still
lacking. Therefore, we set out to determine the measures of
interaction of smoking status (current smokers vs. non-smokers)
and treatment (thrombolysis vs. no thrombolysis) and their
attributable risk in terms of functional recovery 3 month post-




All data comes from the Dutch String-of-Pearls Stroke Study—
a prospective, multicenter cohort study in which patients
FIGURE 1 | Flow-chart diagram illustrating patient selection for current analyses.
with recent stroke presenting within 1-month after symptom
onset are eligible for enrollment following informed consent
(13). Local ethics committees of all participating hospitals
approved the study and all patients provided written informed
consent. Research with this data was performed in accordance
with the Medical Research Involving Human Subjects Act
and codes developed by the Dutch Federation of Medical
Scientific Societies.
Consecutive acute ischemic stroke patients between October
2009 and October 2014 were included for this analysis. Major
inclusion criteria for the current study include the following:
ischemic stroke determined via CT or MRI, known time of
symptom onset, admission within 12 h of symptom onset, and
documented smoking status at the time of the event. Patients
were excluded from the analysis if they received endovascular
therapies or if endovascular treatment status was unknown or
undocumented. A flow diagram shows the patient selection
criteria for this sub-study (Figure 1).
Regression Analyses
We performed regression analyses for binary endpoints by
generalized linear model (glm) using a modified log-Poisson
regression model with a robust error variance to reduce risk
of overestimation (14). These models were used to estimate
relative risks for good functional outcome (mRS ≤ 2), excellent
functional outcome (mRS dichotomized at ≤1), and mortality
3 months post-stroke depending on risk of the exposure
variables (smoking yes/no, thrombolysis yes/no). The two
aforementioned exposure variables create four patient groups
with combined exposures of smoking and treatment (i.e., –
/–, −/+, +/–, and +/+). Crude and adjusted relative risk
(RRs) were calculated for the four patient groups based on
the exposures. Models were adjusted for age, hypertension,
diabetes mellitus, atrial fibrillation, stroke severity (NIHSS), and
stroke etiology.
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TABLE 1 | Basic demographics and baseline clinical parameters of the entire cohort, and sub-groups based on smoking status.
All patients (N = 468) Smokers (N = 143) Non-smokers (N = 325)
Age, mean (SD) 66.2 (13.8) 58.9 (12.7) 69.3 (13.0)
Sex, n (%) female 206 (44.0) 63 (44.1) 143 (44.0)
Cerebrovascular risk factors, n (%)
Diabetes mellitus 78 (16.8) 17(12.1) 61 (18.8)
Hyperlipidemia 119 (26.1) 34 (24.1) 85 (27.0)
Atrial fibrillation 56 (12.1) 9 (6.4) 47 (14.6)
Hypertension 231 (50.1) 58 (40.9) 173 (54.2)
Baseline systolic blood pressure, median mmHg (IQRL) 157 (138–175) 153 (137–178) 157.5 (140–173)
Body weight in kilograms, median IQRL 79 (67–87.5) 80 (69–88) 75 (64–87)
Baseline NIHSS, median (IQRL) 3 (1–6) 3 (1–7) 2 (1–6)
Time to treatment, median (IQRL) 105 (75–150) 100 (72–143) 110 (75–155)
Thrombolysis, n (%) 228 (48.7) 72 (50.3) 156 (48.0)
Infarction in arterial territories, n (%)
ACA 173 (39.1) 55 (41.0) 118 (38.2)
PCA 32 (7.3) 6 (4.5) 26 (8.4)
MCA 105 (23.5) 36 (26.5) 69 (22.2)
Basilar artery 40 (9.0) 13 (9.8) 27 (8.7)
Vertebral artery 20 (4.5) 2 (1.5) 18 (5.8)
Stroke etiology (TOAST), n (%)
Large-artery atherosclerosis 105 (23.5) 33 (24.8) 72 (22.9)
Cardioembolism 88 (23.5) 15 (11.3) 73 (23.3)
Small vessel occlusion 85 (19.7) 36 (27.1) 49 (15.6)
Other 30 (6.7) 10 (7.5) 20 (6.4)
Undetermined 139 (31.1) 39 (29.3) 100 (31.9)
All variables had <5% missing, with TOAST having the largest percentage of missings (i.e., 4.5%). SD, standard deviation; NIHSS, National Institute of Stroke Scale; IQRL, interquartile
range limit; ACA, anterior cerebral artery; PCA, posterior cerebral artery; MCA, middle cerebral artery; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
TABLE 2 | Outcome parameters assessed 3 months post-stroke (good outcome [mRS ≤ 2], excellent outcome [mRS ≤ 1], and mortality), as well as rates of
recanalization and hemorrhagic transformation reported in all patients who received intravenous thrombolysis (N = 228) and based on smoking status.
All patients (N = 228) Smokers (N = 72) Non-smokers (N = 156) Difference smokers—non-smokers (95% CI)
Good outcome at 3 months, n (%) 147 (71.4) 46 (73.0) 101 (70.6) 0.024 (−0.11 to 0.16)
Excellent outcome at 3 months, n (%) 102 (49.5) 27 (42.9) 75 (52.5) −0.96 (−0.25 to 0.05)
Mortality at 3months, n (%) 10 (4.9) 2 (3.2) 8 (5.6) −0.02 (−0.08 to 0.03)
Recanalization, n (%) 22 (25) 9 (29.0) 13 (22.8) 0.06 (−0.14 to 0.26)
Hemorrhagic transformation, n (%) 7 (3.1) 1 (1.4) 6 (3.8) −0.03 (−0.08 to 0.02)
RESULTS
Patient Characteristics
Four hundred sixty-eight patients were included in the final
analysis; 30.6% were smokers. For a detailed description of
basic demographics and baseline parameters of the entire study
group, as well as sub-groups based on smoking-status, refer to
Table 1. Compared to non-smokers, smokers had lower rates
of hypertension, and atrial fibrillation. Stroke etiology differed
significantly between groups; smokers presented with higher
rates of large-artery atherosclerotic strokes compared to non-
smokers who presented with higher rates of cardioembolic
stroke. Infarct localization and stroke severity did not differ
among groups (Table 1).
Generalized Linear Model for Functional
Recovery and Recanalization
In the entire cohort (N = 468), comparing smokers and
non-smokers revealed no significant differences in terms of
good outcome of mRS ≤ 2 (70.6 vs. 72.9%), excellent
outcome of mRS ≤ 1 (46.2 vs. 55.4%), or mortality (4.2 vs.
4.9%). In sub-group analysis including only patients treated
with thrombolysis (N = 228; Table 2), results were similar;
we observed no differences in univariate analysis between
smokers and non-smokers for any of the primary outcome
endpoints. Overall rate of hemorrhagic transformation following
thrombolysis was 3.1%; rates did not differ significantly
between groups.
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TABLE 3 | Relative risks (RR) for a good outcome (modified Rankin Score [mRS] ≤ 2), excellent outcome (mRS ≤ 1), and mortality 3 months post-stroke, presenting
crude, and adjusted values (adjusted for age, presence of hypertension, diabetes mellitus, atrial fibrillation, National Institute of Stroke Scale on admission, stroke etiology
categories).
Thrombolysis Smoking Number of endpoints/total Crude RR (95% CI) Adjusted RR (95% CI)
GOOD OUTCOME mRS ≤ 2
– – 136/162 1 (reference) 1 (reference)
– + 55/68 0.96 (0.84–1.10) 0.93 (0.82–1.05)
+ – 101/143 0.84 (0.74–0.95) 1.06 (0.94–1.20)
+ + 46/63 0.87 (0.74–01.03) 1.08 (0.90–1.30)
EXCELLENT OUTCOME mRS ≤ 1
– – 105/162 1 (reference) 1 (reference)
– + 39/68 0.88 (0.70–1.12) 0.88 (0.70–1.11)
+ – 75/143 0.81 (0.67–0.98) 1.11 (0.91–1.37)
+ + 27/63 0.66 (0.49–0.90) 0.91 (0.65–1.27)
MORTALITY
– – 8/162 1 (reference) –
– + 4/68 1.29 (0.4–3.8) –
+ – 8/143 1.1 (0.4–2.9) –
+ + 2/63 0.6 (0.1–3.0) –
Adjustment was not performed for mortality analyses due to low numbers.
Smoking status had a crude and adjusted RR of 0.99 (95%
CI 0.89–1.11) and 0.96 (95% CI 0.86–1.01) for a good outcome,
respectively. In a sub-group analysis including only patients with
documented recanalization status (N = 88), smoking had a crude
RR of 1.3 (95% CI 0.6–2.7), and an adjusted RR (including
age, time-to-treatment, stroke etiology) of 1.2 (95% CI 0.6–2.7)
for recanalization. Results from the combined exposure analyses
(i.e., Smoking + thrombolysis) for a good outcome (mRS ≤ 2),
excellent outcome (mRS ≤ 1), and mortality 3 months following
the index event are presented in Table 3. In short, no clear
interaction could be observed.
DISCUSSION
We observed no biological interaction of smoking and
intravenous thrombolysis in terms of functional recovery
3 months post-stroke in this multicenter cohort of mild to
moderate ischemic stroke patients admitted within 12 h of
symptom onset.
In all patients, and in sub-group analysis including only
those treated with intravenous thrombolysis, there was no
difference in functional outcome between smokers and non-
smokers in univariate analysis (Table 2). Interestingly, both crude
and adjusted analyses suggest that smoking alone has no effect on
long-term functional recovery post-stroke despite lower clinical
risk profiles of these patients, although the precision of these
analyses is limited. In our combined exposure analyses, smoking
alone had a crude and adjusted RR of 0.88 for an excellent
outcome. The seemingly adverse effect of tPA-administration
alone on functional recovery disappeared when confounding
factors such as stroke severity were considered (crude RR of
0.84 and adjusted RR of 1.06 compared to crude RR of 0.81 and
adjusted RR 1.11 for good and excellent outcome, respectively),
which can be explained by confounding by indication. A
combination of tPA-administration and smoking did not lead
to an improved functional outcome (Table 3). These results are
an indicator that smoking status negatively influences outcome,
regardless of treatment with thrombolysis in this cohort.
Similar to previous reports (3–5, 8), ∼31% of patients
were smokers. As expected, patients with this risk factor had
fewer cerebrovascular comorbidities [hypertension (3, 4, 11)
and AF (11)], and more frequently suffered from large-artery
atherosclerotic strokes (4, 11) (Table 1). Smoking led to increased
recanalization rates in patients treated with thrombolysis in this
cohort [adjusted RR 1.2 (95% CI 0.6–2.7)]. However, due to
small numbers an additive interaction analysis for smoking and
thrombolysis for recanalization could not be performed and
results should be interpreted with caution.
This cohort included predominately minor strokes (median
baseline NIHSS: 3 IQR 1–6). Assuming smoking may modify
treatment effect of thrombolysis by increasing recanalization
rates of large vessel occlusions, any biological interaction of
smoking, and tPAmay have beenmissed in this analysis. Previous
studies that found an enhanced treatment efficacy in smokers
included patients with more severe strokes and higher rates of
proven vessel occlusion (3–6). Therefore, a similar analysis in
an independent cohort of patients with large vessel occlusion is
warranted to further shed light on a possible increased treatment
efficacy of thrombolysis in smokers.
An important limitation of this study is the exclusion of a
large number of patients with undocumented time to treatment.
This is most likely due to the fact that this stroke registry
consists of subacute stroke patients with onset within 30 days,
PSI where time to treatment has less clinical relevancy. This
certainly led to a selection of patients which limits extrapolation
of our results into other populations, notably to those without
known stroke onset. An additional limitation of this analysis
is missing information relevant to our research question (i.e.,
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vessel occlusion size and methods applied for assessment of
recanalization) as well as missing data on pre-treatment glucose
levels and rates of symptomatic intracerebral hemorrhage which
may have influenced functional outcome in these patients (15).
These limitations are inherent to our study design, as data was
retrospectively analyzed from a stroke registry not primarily
designed to address our research aim.
In conclusion, smoking did not modify treatment effect
of thrombolysis in acute ischemic stroke patients in this
cohort. However, a large, multicenter cohort analysis including
patients with proven vessel occlusion and more severe strokes
is warranted to further investigate a potential biological
interaction between smoking and intravenous and intra-
arterial thrombolysis.
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